History, mission and vision
Novogen Ltd (NRT – Australian Stock Exchange; NVGN – NASDAQ) was established in 1994 and generated a series of consumer products and drug discovery development pipelines based on isoflavonoid technology.
Novogen created the subsidiary, Marshall Edwards Inc (MEI) in 2002 and licensed to that company its intellectual property concerning isoflavonoid anti-cancer drugs.
In 2011, Novogen sold all of its intellectual property in relation to isoflavonoid drug technology to MEI which subsequently was renamed MEI Pharma Inc.
Novogen acquired Triaxial Pharmaceuticals Pty Ltd in Dec 2012. Triaxial was established in 2009 by a number of scientists who had overseen the development of the core Novogen intellectual property in oncology drug discovery and development.
The goal of Triaxial was to develop a more efficient and effective drug discovery strategy. This strategy embodied creating a paradigm shift in the design and manufacture of small molecules. To this end, Triaxial developed a novel technology platform that generated important improvements in:
- Efficiency: from design to synthesis to testing.
- Significant improvements in potency outcomes of benzopyran class of molecules.
- Manufacturing efficiencies halving the number of manufacturing steps.
The technology platform underwent proof of concept studies, ensuring it met our stringent requirements in each of the above three goals. These proof of concept studies greatly surpassed our expectations being successful in not only identifying drug candidate hits but also progressing CS-6 as a lead candidate.
Novogen has an equally ambitious program for fast-tracking compounds from the pre-clinical screening programs into the clinic. The Novogen management team has extensive experience in taking compounds from pre-clinical stage to clinical stage programs. The key to efficient transition from pre-clinical to clinical programs is early identification of critical path elements and mitigation of the consequence these elements have on compound transition. Novogen is now committed to progressing CS-6 to the clinic.
The Novogen scientists are of the firm belief that the surface of the technology platform has only been scratched. A balanced approach to the development of CS-6 and a pipeline of new exciting super-benzopyrans is currently being executed. Regular updates on the CS-6 development and the development of our pipeline will be posted in our blogs.
Novogen has set itself the lofty goal of conquering cancer through comprehensive cancer treatment. A bold endeavor that we are passionate about, committed to, and focused on.
Why do we believe we can succeed where so many others have failed?
We believe the technology platform we have developed has the unheralded ability to generate keys that unlock the gates to the pathway to conquering cancer.
Some of those keys we already have, such as:
- The ability to kill cancer cells that are resistant to all other forms of chemotherapy.
- The ability to kill cancer stem cells, believed to be the cells responsible for tumour recurrence following radiotherapy or chemotherapy.
- The potential to reach cancer cells normally protected by barriers such as the blood-brain barrier.
We believe that the successful management of cancer won’t be based on a single master key, but on a range of keys.
CS-6 is the first of those keys, designed specifically to treat the main form of brain cancer – glioblastoma multiforme. It is on the road to the clinic.
An active analog program based on an ability to create increasingly complex modifications of CS-6, is underway. This discovery process has the capability and capacity to deliver a pipeline of drugs for specific cancer conditions.
Novogen has a core group of scientists with extensive experience in the biotechnology industry whose aim is to conduct best-practice science. These scientific endeavors will make a meaningful difference to the lives of cancer patients, which will also reward shareholders that have put their faith in the Company and its technology.